Home › Companies › ZYME

Zymeworks

Market cap $1.78B 69.0M shares (10-Q, Nov 6, 2026) × $25.84 close Nov 17, 2026

Most recent annual filing: 2026-03-02

Catalyst timeline

8 trackedQuarter catalyst calendar →
  1. Zanidatamab NMPA China decision2026Zanidatamab NMPA China decision, 2026, major
  2. ZW191 interim2026ZW191 interim, 2026, notable
  3. ZW1528 IND filing2026ZW1528 IND filing, 2026, notable
  4. YUPELRI/TRELEGY ELLIPTA milestone corporate update1Q 2027YUPELRI/TRELEGY ELLIPTA milestone corporate update, 1Q 2027, routine
  5. TRELEGY ELLIPTA corporate update1Q 2027TRELEGY ELLIPTA corporate update, 1Q 2027, routine
  6. Trelegy Ellipta milestone corporate update1Q 2027Trelegy Ellipta milestone corporate update, 1Q 2027, routine
  7. R&D Day corporate updateFeb 11, 2027R&D Day corporate update, Feb 11, 2027, routine
  8. Pasritamig J&J Ph3 startDec 2027Pasritamig J&J Ph3 start, Dec 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (12 active programs)

Technology platforms

Azymetric

Multispecific antibody platform enabling bispecific and trispecific antibody development with dual-targeting of receptors/ligands; foundation for ADCs and MSATs in oncology, inflammation, and autoimmune disease; partnered with GSK, Daiichi Sankyo, J&J, and Merck

Targets: HER2

EFECT

Antibody effector function modulation platform consisting of Fc region modifications enabling selective enhancement or suppression of immune effector function; used in oncology, inflammation, and autoimmune therapeutics

ProTECT

Conditionally active antibody technology that masks an antibody arm outside the tumor to minimize off-target effects; activates in tumor microenvironment via protease cleavage; designed to improve therapeutic window in oncology

Pan-RAS ADC

Proprietary Pan-RAS antibody-drug conjugate (ADC) platform; company evaluating formation of a separate dedicated entity with third-party capital to advance multiple product candidates into clinical studies.

Targets: RAS

TriTCE Co-Stim

Trispecific T cell engager co-stimulation platform used to configure T cell engagers targeting tumor antigens with simultaneous CD3 and CD28 engagement; focus on solid tumors and DLL3-expressing cancers

Targets: DLL3, CD3, CD28

Drug Conjugate Platforms

Suite of proprietary cytotoxins (topoisomerase and microtubulin inhibiting toxins), stable linkers, and conjugation technologies for ADC development in oncology; includes novel TOPO1i payload ZD06519

Discontinued (1)

Capital (as filed)

Cash
$100M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$24.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$573M cash per the update of Aug 25, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (8)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (8 calls)

Every verdict Biotech Distilled has published on Zymeworks, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Zymeworks Inc. (ZYME) — Scientific Deep Dive for Zanidatamab (Ziihera®), ZW191, and the Royalty-Aggregation Pipeline Zanidatamab is approved and milestone-rich but the royalty-aggregation model is unproven and the balance sheet is heavily leveraged; wait for the Aug 25 PDUFA to confirm the flywheel.
  2. Speculative buy speculative UPDATE: Zymeworks (ZYME) - The Runway Guidance Just Disappeared Stock is 13% lower than a month ago, below management's own buyback price, going into a well-telegraphed approval that unlocks $250M, but withdrawn runway guidance and $77.7M Q2 cash burn keep conviction speculative.
  3. Buy core UPDATE: Zymeworks (ZYME) - The Flywheel Caught FDA approved zanidatamab with a broader-than-expected label (IHC 2+/ISH+, no PD-L1 gate), the $250M milestone is earned, and the argument shifts from 'a milestone is coming' to 'the franchise is bigger than modeled.'
  4. Buy core UPDATE: Zymeworks (ZYME) - Theravance Is In the Building Theravance acquisition closed, removing the last named execution risk; the OMERS financing keeps the parent balance sheet out of lenders' reach and is sized to be repaid before YUPELRI generics arrive.
  5. Buy core UPDATE: Zymeworks (ZYME) - Roche Buys the Trispecific Roche's $55M upfront for ZW209 validates the out-licensing model and delivers $95M of near-term non-dilutive cash, but the core royalty ramp thesis is unchanged.
  6. Buy core UPDATE: Zymeworks (ZYME) - ZW191 Survives Contact Randomized ZW191 data (n=80) confirmed a 64.5% response rate at the lower dose with half the severe toxicity, giving the banker a stronger package to sell, but value only materializes through a deal not yet signed.
  7. Buy core UPDATE: Zymeworks (ZYME) - The Royalty Line Prints Mature OS data (HR 0.65) largely removes clinical risk on the GEA franchise, royalties grew to $2.3M in the first partial quarter of the new label, and insiders bought ~$66M near $28, but recurring revenue still doesn't cover the business.
  8. Buy core UPDATE: Zymeworks (ZYME) - The Milestones Become Buybacks A new $200M buyback funded by the Roche and Trelegy milestones signals management confidence after a 14.8% drawdown, but recurring cash still doesn't cover the business and the program depends on two milestones not yet received.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (4 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (31)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)